

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 03-764-B (400.216US) )**

<b>In application of:</b>	)	
	)	
<b>Chowrira, et al.</b>	)	
	)	<b>Examiner: TBA</b>
<b>Serial No.: 10/567,888</b>	)	
	)	<b>Group Art Unit: 1645</b>
<b>Filed: February 7, 2006</b>	)	
	)	<b>Conf. No. 2856</b>
<b>For: RNA interference mediated inhibition of Xiap Gene</b>	)	
<b>Expression using Short Interfering Nucleic Acid</b>	)	
<b>(siNA)</b>	)	

**REQUEST FOR CORRECTED FILING RECEIPT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attention: Application Processing Division  
Customer Correction Branch

Dear Sir:

1. Attached is a copy of the official filing receipt received from the PTO in the above-referenced application for which issuance of a corrected filing receipt is respectfully requested.
2. There is an error with respect to the following data, which is incorrectly entered.

**Error In**

**Domestic Priority data as claimed by applicant**

This application is a 371 of PCT/US04/25589 08/06/2004  
Which claims the benefit of 60/493,561 08/08/2003  
And claims the benefit of 60/543,480 02/10/2004  
And is a CIP of 10/826,966 04/16/2004  
Which is a CIP of 10/757,803 01/14/2004  
Which is a CIP of 10/720,448 11/24/2003 ABN  
Which is a CIP of 10/693,059 10/23/2003 ABN  
Which is a CIP of 10/444,853 05/23/2003  
And is a CIP of 10/652,791 08/29/2003  
Which is a CON of 10/422,704 04/24/2003 ABN

Which is a CON of 10/417,012 04/16/2003 ABN  
And said 10/826,966 04/16/2004  
Is a CIP of PCT/US03/05346 02/20/2003  
And is a CIP of PCT/US03/05028 02/20/2003  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/358,580 02/20/2002  
And said PCT/US03/05028 02/20/2003  
Claims benefit of 60/358,580 02/20/2002  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/363,124 03/11/2002  
And said PCT/US03/05028 02/20/2003  
Claims benefit of 60/363,124 03/11/2002  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/386,782 06/06/2002  
And said PCT/US03/05028 02/20/2003  
Is a CIP of 60/386,782 06/06/2002  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/406,784 08/29/2002  
And said PCT/US03/05028 02/20/2003  
Claims benefit of 60/406,784 08/29/2002  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/408,378 09/05/2002  
And said PCT/US03/05028 02/20/2003  
Claims benefit of 60/408,378 09/05/2002  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/409,293 09/09/2002  
And said 10/826,966 04/16/2004  
Is a CIP of 10/780,447 02/13/2004  
Which is a CIP of 10/427,167 04/30/2003  
And is a CIP of PCT/US02/15876 05/17/2002  
Which claims benefit of 60/292,217 05/18/2001  
And claims benefit of 60/362,016 03/06/2002  
And claims benefit of 60/306,883 07/20/2001  
And claims benefit of 60/311,865 08/13/2001  
And said 10/826,996 04/16/2004  
Is a CIP of 10/727,780 12/03/2003  
And claims the benefit of 60/543,480 02/10/2004

## Correct Data

### **Domestic Priority data as claimed by applicant**

This application is a 371 of PCT/US04/25589 08/06/2004  
Which claims the benefit of 60/493,561 08/08/2003  
**This application is a CIP of PCT/US04/16390 05/24/2004**  
**Which** is a CIP of 10/826,966 04/16/2004  
Which is a CIP of 10/757,803 01/14/2004  
Which is a CIP of 10/720,448 11/24/2003 ABN  
Which is a CIP of 10/693,059 10/23/2003 ABN  
Which is a CIP of 10/444,853 05/23/2003  
**Which** is a CIP of PCT/US03/05346 02/20/2003  
And is a CIP of PCT/US03/05028 02/20/2003  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/358,580 02/20/2002  
And said PCT/US03/05028 02/20/2003  
Claims benefit of 60/358,580 02/20/2002  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/363,124 03/11/2002  
And said PCT/US03/05028 02/20/2003  
Claims benefit of 60/363,124 03/11/2002  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/386,782 06/06/2002  
And said PCT/US03/05028 02/20/2003  
**Claims** benefit of 60/386,782 06/06/2002  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/406,784 08/29/2002  
And said PCT/US03/05028 02/20/2003  
Claims benefit of 60/406,784 08/29/2002  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/408,378 09/05/2002  
And said PCT/US03/05028 02/20/2003  
Claims benefit of 60/408,378 09/05/2002  
And said PCT/US03/05346 02/20/2003  
Claims benefit of 60/409,293 09/09/2002  
**And said PCT/US03/05028 02/20/2003**  
**Claims the benefit of 60/409,293 09/09/2002**  
**And said PCT/US03/05346 02/20/2003**  
**Claims benefit of 60/440,129 01/15/2003**  
**And said PCT/US03/05028 02/20/2003**  
**Claims benefit of 60/440,129 01/15/2003**  
**This application is a CIP of PCT/US04/13456 04/30/2004**  
**Which is a continuation of 10/780,447 02/13/2004**  
Which is a CIP of 10/427,167 04/30/2003  
**Which** is a CIP of PCT/US02/15876 05/17/2002  
Which claims benefit of 60/292,217 05/18/2001  
And claims benefit of 60/362,016 03/06/2002

And claims benefit of **60/363,883** 07/20/2001

And claims benefit of 60/311,865 08/13/2001

**This application** is a CIP of 10/727,780 12/03/2003

**This application** claims the benefit of 60/543,480 02/10/2004

3. The correction is not due to any error by applicant and no fee is due.

Respectfully submitted,

Date: October 9, 2007

/Lisa M.W. Hillman/

Lisa M.W. Hillman, Ph.D

Registration No. 43,673



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO	FILING OR 371(c) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	TOT CLMS	IND CLMS
10/567,888 ✓	12/15/2006 ✓	1635	1115	03-764-B (400.216US) ✓	35	1

CONFIRMATION NO. 2856

65778

MCDONNELL, BOEHNNEN, HULBERT AND BERGHOFF, LLP  
300 SOUTH WACKER DRIVE  
SUITE 3100  
CHICAGO, IL 60606

CORRECTED FILING RECEIPT

DOCKETED



\*OC000000025048189\*

AUG - 1 2007

DUE DATE:                       
BY:                     

Date Mailed: 07/27/2007

Receipt is acknowledged of this nonprovisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

## Applicant(s)

Bharat M. Chowrira, San Francisco, CA; ✓  
James McSwiggen, Broomfield, CO; ✓

## Assignment For Published Patent Application

Sirna Therapeutics, Inc., Boulder, CO ✓

**Power of Attorney:** The patent practitioners associated with Customer Number 20306.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/25589 08/06/2004 ✓

which claims benefit of 60/493,561 08/08/2003 ✓

~~and claims benefit of 60/543,480 02/10/2004~~ ✓

and is a CIP of 10/826,966 04/16/2004 ✓

which is a CIP of 10/757,803 01/14/2004 ✓

which is a CIP of 10/720,448 11/24/2003 ABN ✓

which is a CIP of 10/693,059 10/23/2003 ABN ✓

which is a CIP of 10/444,853 05/23/2003 ✓

~~and is a CIP of 10/652,791 08/29/2003~~

~~which is a CON of 10/422,704 04/24/2003 ABN~~

~~which is a CON of 10/417,012 04/16/2003 ABN~~

and said 10/826,966 04/16/2004

is a CIP of PCT/US03/05346 02/20/2003 ✓

and is a CIP of PCT/US03/05028 02/20/2003 ✓

and said PCT/US03/05346 02/20/2003 ✓

claims benefit of 60/358,580 02/20/2002 ✓

*This application  
is a CIP of  
PCT/US04/10390  
05/24/04*

*entered twice - needs to be removed*

and said PCT/US03/05028 02/20/2003 ✓  
 claims benefit of 60/358,580 02/20/2002 ✓  
 and said PCT/US03/05346 02/20/2003 ✓  
 claims benefit of 60/363,124 03/11/2002 ✓  
 and said PCT/US03/05028 02/20/2003 ✓  
 claims benefit of 60/363,124 03/11/2002 ✓  
 and said PCT/US03/05346 02/20/2003 ✓  
 claims benefit of 60/386,782 06/06/2002 ✓  
 and said PCT/US03/05028 02/20/2003 ✓  
 is a CIP of 60/386,782 06/06/2002 ✓  
 and said PCT/US03/05346 02/20/2003 ✓  
 claims benefit of 60/406,784 08/29/2002 ✓  
 and said PCT/US03/05028 02/20/2003 ✓  
 claims benefit of 60/406,784 08/29/2002 ✓  
 and said PCT/US03/05346 02/20/2003 ✓  
 claims benefit of 60/408,378 09/05/2002 ✓  
 and said PCT/US03/05028 02/20/2003 ✓  
 claims benefit of 60/408,378 09/05/2002 ✓  
 and said PCT/US03/05346 02/20/2003 ✓  
 claims benefit of 60/409,293 09/09/2002 ✓  
~~and said 10/826,966 04/16/2004~~  
~~is a CIP of 10/780,447 02/13/2004~~  
~~which is a CIP of 10/427,160 04/30/2003~~  
 and is a CIP of PCT/US02/15876 05/17/2002 ✓  
 which claims benefit of 60/292,217 05/18/2001 ✓  
 and claims benefit of 60/362,016 03/06/2002 ✓  
 and claims benefit of 60/306,883 07/20/2001 ✓  
 and claims benefit of 60/311,865 08/13/2001 ✓  
 and said 10/826,966 04/16/2004  
 is a CIP of 10/727,780 12/03/2003 ✓  
 and claims benefit of 60/543,480 02/10/2004 ✓

And said PCT/US03/05028 02/20/03  
 Claims the benefit of 60/409,293  
 9/09/02

and said PCT/US03/05346 02/20/03  
 Claims benefit of 60/440,129 1/15/03

and said PCT/US03/05028 2/20/03  
 Claims benefit of 60/440,129 01/15/03

This application is a CIP of  
 PCT/US04/13450 04/30/04  
 to be used for filing abroad under the Paris  
 Convention, which is a continuation of  
 10/780,447 02/13/04

which is a CIP of 10/427,167 04/30/03

## Foreign Applications

If Required, Foreign Filing License Granted: 01/16/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/567,888**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

**\*\* SMALL ENTITY \*\***

## Title

Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid .  
 (sina)

## Preliminary Class

514

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).